NCT05215665

GEMOX Combined With Targeted Therapy and Immunotherapy for Patients With Advanced Cholangiocarcinoma

Efficacy, Safety Evaluation and Biomarker Screening of GEMOX Combined With Targeted Therapy and Immunotherapy for Patients With Advanced Cholangiocarcinoma

• Status: Recruiting
• Phase: N/A
• Study type: Interventional
• Enrollment: 146 (estimated)
• Sponsor: Tianjin Medical University Cancer Institute and Hospital · Academic / Other
• Sex: All
• Age: 18 Years – 70 Years
• Healthy volunteers: Not accepted

Summary

The clinical trial is designed to evaluate the safety and efficacy of GEMOX combined with targeted therapy and immunotherapy for patients with advanced cholangiocarcinoma, and screen the potential biomarkers

Conditions

• Cholangiocarcinoma

Interventions

Type	Name	Description
DRUG	GEMOX Regimen	Oxaliplatin 100mg/m2 IV d1 Q3W+ gemcitabine 1000mg/m2 IV d1/8 Q3W
DRUG	Lenvatinib	8/12mg PO QD continuously
DRUG	Toripalimab	240mg IV d1 Q3W

Timeline

• Start date: 2022-01-15
• Primary completion: 2024-05-15
• Completion: 2026-01-15
• First posted: 2022-01-31
• Last updated: 2024-12-11

Locations

1 site across 1 country: China